Article Menu

Export Article

More by Authors Links

Article Data

  • Views 524
  • Dowloads 142

Case Reports

Open Access

Very long response with trastuzumab for metastaticHer2-positive breast cancer

  • F. Lai-Tiong1,*,

1 Oncology Unit Gard Cancer Institute, NÎmes, France

DOI: 10.12892/ejgo4040.2018 Vol.39,Issue 6,December 2018 pp.1002-1003

Published: 15 December 2018

*Corresponding Author(s): F. Lai-Tiong E-mail: florencelt@hotmail.fr

PDF (85.79 kB)

Abstract

Metastatic Her2-positive breast cancer are very aggressive tumors. With the development of anti-Her2 therapies, the prognosis of such tumors has changed. The author reports the case of a 60-year-old woman, diagnosed with a left Her2-positive breast cancer, revealed by a pathological fracture of the right femur (pT1cN1aM1, Stage IV). She received hormonal treatment in association with trastuzumab. She always is under trastuzumab therapy for four years. Anti-Her2 therapies are effective even in metastatic cancer patients.

Keywords

Her2-positive; Breast cancer; Metastasis; Trastuzumab; Long response; Targeted therapy.

Cite and Share

F. Lai-Tiong. Very long response with trastuzumab for metastaticHer2-positive breast cancer. European Journal of Gynaecological Oncology. 2018. 39(6);1002-1003.

URL:

https://www.ejgo.net/articles/10.12892/ejgo4040.2018

References

[1] Dawood S, Broglio K, Buzdar AU, Hortobagyi G.N., Giordano S.H.: “Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review”. J. Clin. Oncol., 2010, 28, 92.

[2] Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L., D'Amico R.: “Trastuzumab-containing regimens for metastatic breast cancer”. Cochrane Database Syst. Rev., 2014, 6, CD006242.

[3] Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al.: “Pertuzumab plus docetaxel for metastatic breast cancer”. N. Engl. J. Med., 2012, 366, 109.

[4] Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al.: “Pertuzumab, trastuzumab, and docetaxel in Her2-positive metastatic breast cancer”. N. Engl. J. Med., 2015, 372, 724.

[5] Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al.: “Trastuzumab emtansine for Her2-positive advanced breast cancer”. N. Engl. J. Med., 2012, 367, 1783.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top